Quest Diagnostics Launches Innovative Blood Test for Alzheimer's Disease Assessment

Quest Diagnostics Enhances Alzheimer's Care with New Blood Tests

Quest Diagnostics, a prominent player in diagnostic information services, has recently unveiled two significant additions to its Quest AD-Detect® portfolio, aiming to improve Alzheimer’s disease assessment. This initiative not only broadens the accessibility of essential blood tests for symptomatic patients but also aligns with the company's goal of setting new standards in Alzheimer’s diagnostics.

Introduction of FDA-Cleared Elecsys pTau217 Blood Test

The highlight of this announcement is the introduction of the FDA-cleared Elecsys® Phospho-Tau (217P) plasma (pTau217) blood test. This test is recognized as the first FDA-cleared single-assay biomarker test that aids in both the confirmation and exclusion of amyloid pathology in patients. By utilizing validated clinical cutoffs appropriate for various medical settings, this innovative test represents a leap forward in diagnosing Alzheimer’s.

Beginning in the fourth quarter of this year, Quest intends to make the Elecsys pTau217 test available through its extensive network of services to physicians and clinical trial collaborators nationwide. This initiative is expected to enhance diagnostic certainty, allowing healthcare providers to offer more effective care to patients experiencing Alzheimer’s symptoms.

Michael K. Racke, MD, a board-certified neurologist at Quest Diagnostics, emphasized, "Blood-based biomarker testing has rapidly set a new standard of care for guiding treatment and diagnosis decisions for Alzheimer's disease." This reflects the company’s dedication to integrating new technologies and innovations from reliable collaborators like Roche into their evolving diagnostics portfolio.

Launch of the Multi-Biomarker AD-Detect Test

In conjunction with the FDA breakthrough, Quest is set to launch a comprehensive multi-biomarker lab-developed test known as AD-Detect® ABeta 42/40, p-tau217, and ApoE Evaluation. Scheduled for release by the end of this month, this test will assess multiple biomarkers to predict the likelihood of Alzheimer’s pathology more accurately.

The new test combines results from the pTau217 assay with quantitative results from amyloid beta 42/40 and genetic markers like these from the ApoE isoform. Research published in Neurology® Clinical Practice, underscoring the reliability of this test, indicates its sensitivity and specificity rate at around 90%, allowing it to confirm Alzheimer’s diagnosis effectively without necessitating additional tests.

Benefits of Blood-Based Testing Over Traditional Methods

Quest’s recent studies indicate that blood-based biomarker testing is not only more efficient but also less costly compared to traditional diagnostic methods such as positron emission tomography-computed tomography (PET-CT) scans or cerebrospinal fluid (CSF) analyses. As healthcare costs and accessibility issues continue to rise, these innovative blood tests offer a practical alternative that can be administered at more locations, including Quest’s extensive patient service centers across the United States.

Patients can conveniently undergo testing at approximately 2,000 Quest locations, or through their physician offices—with mobile phlebotomy services also available. This accessibility could significantly impact patient outcomes by fostering earlier detection and intervention strategies for Alzheimer’s disease.

Conclusion

Quest Diagnostics is at the forefront of enhancing Alzheimer's disease diagnosis with its latest contributions to blood-based testing. With the new Elecsys pTau217 test and the multi-biomarker AD-Detect options, the company is paving the way for improved patient care and informed healthcare decisions. This commitment to innovation not only benefits clinicians and clinical trials but ultimately leads to better health outcomes for patients.

To learn more about the offerings from Quest AD-Detect, visit www.QuestForTheCure.com.

Through its robust research and dedication to advancing diagnostic methodologies, Quest Diagnostics continues to be a trusted partner in the fight against Alzheimer’s, emphasizing its mission to connect people with essential health insights.